Kura Oncology (KURA) closed at $6.91 on November 20, 2026, down 6.0% from the previous close, on volume of 1,551,030 shares (30-day average 2,139,533).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 11, 2026 | Call Spread | 21-Jan-288 : 15 C | 644 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
UBS Sticks to Their Buy Rating for Kura Oncology (KURA)
TipRanks (Fri, 20-Nov 6:46 AM ET)
TipRanks (Tue, 17-Nov 7:10 AM ET)
Kura Oncology to Participate in Two Investor Conferences in November
Globe Newswire (Fri, 13-Nov 12:33 PM ET)
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Globe Newswire (Tue, 10-Nov 4:02 PM ET)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 7:30 AM ET)
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Globe Newswire (Wed, 4-Nov 9:02 AM ET)
Kura Oncology to Report Third Quarter Financial Results on November 10
Globe Newswire (Tue, 3-Nov 6:58 AM ET)
Market Chameleon (Tue, 13-Oct 7:32 AM ET)
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
Globe Newswire (Tue, 13-Oct 7:30 AM ET)
Globe Newswire (Wed, 7-Oct 7:15 AM ET)
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
Kura Oncology trades on the NASDAQ stock market under the symbol KURA.
As of November 20, 2026, KURA stock price declined to $6.91 with 1,551,030 million shares trading.
KURA has a beta of 1.81, meaning it tends to be more sensitive to market movements. KURA has a correlation of 0.16 to the broad based SPY ETF.
KURA has a market cap of $634.88 million. This is considered a Small Cap stock.
Last quarter Kura Oncology reported $23 million in Revenue and -$.78 earnings per share. This fell short of revenue expectation by $-716,088 and exceeded earnings estimates by $.03.
In the last 3 years, KURA traded as high as $24.17 and as low as $5.41.
The top ETF exchange traded funds that KURA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
KURA has underperformed the market in the last year with a return of -37.1%, while the SPY ETF gained +6.9%. In the last 3 month period, KURA fell short of the market, returning -41.0%, while SPY returned -9.3%. However, in the most recent 2 weeks KURA has outperformed the stock market by returning -5.0%, while SPY returned -6.2%.
KURA support price is $6.94 and resistance is $7.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KURA shares will trade within this expected range on the day.